Diagnostic and Interventional Cardiology DAIC

Diagnostic and Interventional Cardiology (DAIC) is a magazine that reaches more than 25,000 healthcare professionals in cardiology, interventional cardiology and cath labs across the United States. These influential buying team members rely on DAIC's award-winning editorial content and comparison charts as a unique research tool for specifying, recommending and approving technology/device purchases.

Silence Therapeutics has announces positive topline 36-week data from its ongoing Phase 2 Study of Zerlasiran in patients with high Lipoprotein(a), reporting that the study met the primary endpoint and demonstrated highly significant reductions in Lp(a) to week 36.

News | Cardiovascular Clinical Studies

Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lp(a) Announced by Silence Therapeutics

March 13, 2024 — Silence Therapeutics has announced positive topline 36-week data from the ongoing ALPACAR-360 phase 2 ...

March 13, 2024

Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact, today announced that it has launched its Tapered ENROUTE Transcarotid Stent System to hospitals in the United States

News | Structural Heart

New Late-breaking Data from Medtronic Evolut Low Risk Trial Demonstrate Strong Clinical and Cost-effectiveness Benefits of TAVR Platform

March 12, 2024 — Medtronic plc, a global leader in healthcare technology, today announced two late-breaking data ...

March 12, 2024

Getinge has announced the U.S. Food and Drug Administration’s (FDA) 510(k) clearance of the Vasoview Hemopro 3, the latest addition to the medtech company’s endoscopic vessel harvesting (EVH) solutions.

News | FDA

Getinge Announces US FDA 510(k) Clearance for Vasoview Hemopro 3 Endoscopic Vessel Harvesting (EVH) solution

March 12, 2024 — Getinge has announced the U.S. Food and Drug Administration’s (FDA) 510(k) clearance of the Vasoview ...

March 12, 2024

The U.S. Food and Drug Administration (FDA) announced that Abbott is recalling its HeartMate Touch System (version 1.0.32) for risk of unexpected pump stop or start. Issues may occur if the HeartMate Touch System is disconnected from a patient’s HeartMate Controller while a “pump stop” command is running. People who have the implantable HeartMate 3 Left Ventricular Assist Device may be affected.

News | FDA

FDA Announces Abbott Recall of HeartMate Touch Communication System for Unintentional Pump Start and Stop

March 12, 2024 — The U.S. Food and Drug Administration (FDA) announced that Abbott is recalling its HeartMate Touch ...

March 12, 2024

VahatiCor, Inc., a med tech company dedicated to helping patients with persistent ischemic heart disease, has announced the treatment of the first patient with the A-FLUX Reducer System, a treatment for patients with angina or chest pain.

News | Cardiovascular Business

VahatiCor, Inc. Announces Treatment of First Patient with the A-FLUX Reducer System Innovation for Patients Suffering from Angina Due to Persistent Ischemic Heart Disease

March 11, 2024 — VahatiCor, Inc., a med tech company dedicated to helping patients with persistent ischemic heart ...

March 11, 2024

Georgia Tech-led effort to improve support device options for end-stage heart failure

News | Heart Failure

The Texas Heart Institute Collaborates on Multi-institutional DOD Grant to Develop Novel Left Ventricular Assist Device

March 8, 2024 — The Texas Heart Institute, Georgia Institute of Technology (Georgia Tech), North Carolina State ...

March 08, 2024

News | Stents

Silk Road Medical Expands TCAR Portfolio with Launch of Tapered ENROUTE Transcarotid Stent System

March 8, 2024 — Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact ...

March 08, 2024

The approval is based on the results of SELECT, the largest cardiovascular outcomes trial ever completed for people with obesity and known heart disease

News | FDA

FDA Approves Wegovy for Cardiovascular Risk Reduction in Adults with Known Heart Disease and Overweight or Obesity

March 8, 2024 — Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved an additional ...

March 08, 2024

CardiAMP cell therapy-treated patients had 37% relative risk reduction in heart death equivalent (death, heart transplant, left ventricular assist device implantation) and 9% relative risk reduction in non-fatal major adverse cardiac and cerebrovascular events

News | FDA

Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

March 7, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions for ...

March 07, 2024

An AMA letter sent to Secretary Bacerra outlines ongoing concerns of physicians amidst the cybersecurity incident that has impacted Change Healthcare

News | Cybersecurity

As Cyberattack Jeopardizes Physician Practices, AMA Demands Action

March 6, 2024 — As the cyber-takedown of Change Healthcare has forced medical practices to go without revenue for a ...

March 06, 2024

Bodyport Inc., a biomarker-guided predictive care company, has presented data showing its FDA-cleared, non-invasive, biomarker-based technology for remote heart failure monitoring detected twice as many heart failure events as compared to the weight-based standard of care.

News | Cardiovascular Clinical Studies

Bodyport Presents Preliminary Analysis of SCALE-HF 1 Study on Remote Heart Failure Monitoring at Technology and Heart Failure Therapeutics (THT) Conference

March 6, 2024 — Bodyport Inc., a biomarker-guided predictive care company focused on heart failure, announced data from ...

March 06, 2024

Feature

One on One ... with Hal Wolf, FHIMSS

Industry trade shows and conferences seem to be making their comeback. The Healthcare Information and Management Systems ...

March 06, 2024

A look at DAIC's top-viewed content for February 2024

Feature | Cardiovascular Business | By Melinda Taschetta-Millane

A Look at February's Top 10

February was a short but busy month in the diagnostic and interventional cardiology world, with a lot of news being ...

March 05, 2024

FIRE1 announced that it has completed patient enrollment in the U.S. Early Feasibility Study (FUTURE-HF2) of its FIRE1 System for remote heart failure monitoring.

News | Heart Failure

FIRE1 Completes Enrollment in US Early Feasibility Study of Innovative Remote Heart Failure Monitoring System

March 5, 2024 — FIRE1 announced that it has completed patient enrollment in the U.S. Early Feasibility Study (FUTURE ...

March 05, 2024

Maternal stress may lead to adverse changes in mental, physical health that impact development of the fetal heart

News | Pediatric Cardiology

Severe Maternal Grief Associated with Increased Risk of Heart Failure in Child

March 1, 2024 — Prenatal stress is a potential risk factor for cardiovascular disease in offspring later in life. In a ...

March 01, 2024